DAO and schizophrenia: In this review, we aim to present an update on the current understanding of the aetiopathogenesis of schizophrenia, along with the most promising novel agents in the treatment of this disorder, namely olanzapine/samidorphan, lumateperone, brilaroxazine, xanomeline/trospium, emraclidine, ulotaront, pimavanserin, sodium benzoate, other DAAO inhibitors, D-serine, and iclepertin.